Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992 Jun 01;79(11):3067-70

Date

06/01/1992

Pubmed ID

1586748

Scopus ID

2-s2.0-0026636931 (requires institutional sign-in at Scopus site)   179 Citations

Abstract

Philadelphia chromosome (Ph1)-positive acute lymphoblastic leukemia (ALL) has a poor prognosis when treated with conventional chemotherapy. We analyzed the outcome of 67 HLA-identical sibling bone marrow transplants (BMTs) for Ph1-positive ALL reported to the International Bone Marrow Transplant Registry (IBMTR). Twenty-one of 67 (31%) transplant recipients survived in continuous complete remission more than 2 years after transplant. Two-year actuarial probabilities (95% confidence interval) of leukemia-free survival were 38% (23% to 55%) for 33 patients transplanted in first remission, 41% (23% to 61%) for 22 patients transplanted after relapse, and 25% (9% to 53%) for 12 patients failing to achieve remission with conventional chemotherapy. These data indicate that transplants are effective treatment for Ph1-positive ALL.

Author List

Barrett AJ, Horowitz MM, Ash RC, Atkinson K, Gale RP, Goldman JM, Henslee-Downey PJ, Herzig RH, Speck B, Zwaan FE

Author

Mary M. Horowitz MD, MS Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Adult
Bone Marrow Transplantation
Child
Child, Preschool
Graft vs Host Disease
Humans
Middle Aged
Neoplasm Recurrence, Local
Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Remission Induction